Terminal2 · Diagnosis Card #00

[Diagnosis Name]

A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of frontotemporal dementia at end of life. What the hospice team needs to understand on day one.

Age of Onset
45–65 yr
Mean age at diagnosis approximately 58 years. FTD is the most common cause of dementia in people under 65, accounting for 20–50% of early-onset dementia cases. The person who receives this diagnosis is statistically likely to still be employed, still carrying a mortgage, still parenting, and still financially supporting a family.[1]
FTD Prevalence
50–60K
Estimated Americans affected. FTD accounts for 10–20% of all dementia cases. Substantially underdiagnosed — average diagnostic delay is 3–4 years, during which psychiatric misdiagnosis (bipolar disorder, depression, personality disorder) is the norm.[2]
Survival by Variant
2–12 yr
bvFTD median 6–11 years; svPPA median 8–12 years; nfvPPA median 7–10 years; FTD-ALS median 2–3 years from symptom onset — the most rapidly fatal variant and the one most likely to present to hospice within months of diagnosis.[3]
Genetic Burden
~40%
Approximately 40% of FTD cases are familial — far higher than Alzheimer's disease. Major genes: C9orf72, GRN, MAPT. Most follow autosomal dominant inheritance. Adult children of an affected patient have a 50% probability of carrying the mutation.[4]

Frontotemporal dementia is not a single disease but a clinical syndrome encompassing multiple pathologically and genetically distinct conditions unified by their preferential destruction of the frontal and temporal lobes. The major clinical subtypes are: behavioral variant FTD (bvFTD — the most common, approximately 50–60% of cases, characterized by progressive personality transformation, disinhibition, apathy, loss of empathy, compulsive behavior, hyperorality, and executive dysfunction with relatively preserved memory early), semantic variant primary progressive aphasia (svPPA — selective loss of word and object meaning with fluent but empty speech), nonfluent/agrammatic variant primary progressive aphasia (nfvPPA — effortful, halting speech with agrammatism and apraxia of speech), and FTD with motor neuron disease (FTD-ALS — approximately 15% of FTD patients develop concurrent ALS, compressing the entire disease course to 2–3 years with respiratory failure as the terminal event).[1]

What makes FTD unique in hospice is not its terminal management — which shares features with other dementias — but the catastrophic social, relational, financial, and legal devastation that precedes the terminal stage. The patient is typically in their 50s, still working, still raising children, still carrying debt. The behavioral symptoms that led to the diagnosis were first interpreted as professional misconduct, a moral failing, a psychiatric disorder, or a marriage in crisis. By the time the diagnosis is made, the family has already lost income, possibly lost housing, possibly lost the marriage, and certainly lost the person they knew. The hospice clinician who walks into an FTD home is not walking into the end of a long illness — they are walking into the wreckage of a life interrupted, a family system never designed for this, and a grief with no cultural script.[2]

🧭 Clinical framing

The behavioral variant FTD family does not experience the grief of watching a person gradually fade — they experience the grief of watching their person become someone entirely different. Someone who says cruel things without awareness, who has no empathy, who is sexually or socially disinhibited, who does not recognize the rules that defined them. Memory may be intact. Conversational ability may be intact. The person can still talk — but they are no longer the person the family knew. This is replacement, not fading, and it is a specific grief that the hospice clinician must name. The PPA family experiences a different grief: watching language — and with it, the ability to express needs, fears, and love — slowly extinguish while cognition may remain partially intact. The FTD-ALS family faces the fastest timeline: behavioral or language deterioration compounded by progressive paralysis and respiratory failure within 2–3 years.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"The first FTD home I walked into, the patient was 57 and his wife was 54. Their kids were still in college. The mortgage was three years from paid off. He'd spent two years before the diagnosis being investigated at work because the disinhibition looked like corruption. His wife had been told by three different doctors it was depression. Nobody had told the adult children they had a 50% chance of carrying the same mutation. That's what this disease does — it destroys the life before it destroys the brain. When I sat down and named all of it — the diagnostic odyssey, the financial wreckage, the genetic risk, the grief they didn't have a word for — his wife looked at me and said, 'You're the first person who has told us what actually happened to us.' That naming is the clinical act. Everything else follows from it."
— Waldo, NP · Terminal2
S02Clinician

How It's Diagnosed

Diagnostic criteria, neuroimaging, genetic testing, and what to look for in hospice records. Most FTD patients arrive with an established diagnosis after a prolonged diagnostic odyssey — this section helps you read it and identify what is still missing.

Diagnostic Criteria from Records
  • bvFTD — Rascovsky et al. 2011: Possible bvFTD requires ≥3 of 6 features: behavioral disinhibition, apathy/inertia, loss of sympathy or empathy, perseverative/stereotyped/compulsive behavior, hyperorality and dietary changes, executive neuropsychological profile with relative sparing of memory and visuospatial functions. Probable bvFTD additionally requires functional decline plus neuroimaging showing frontal or anterior temporal atrophy or hypometabolism. Definite bvFTD requires histopathological confirmation or a known pathogenic mutation.[5]
  • PPA variants — Gorno-Tempini et al. 2011: nfvPPA requires ≥1 of effortful agrammatic speech or apraxia of speech, plus neuroimaging showing left posterior frontal/insular atrophy. svPPA requires impaired confrontation naming and single-word comprehension, plus anterior temporal atrophy (left > right). Logopenic variant PPA (lvPPA) is most commonly Alzheimer's pathology and is not typically classified as FTD.[6]
  • FTD-ALS overlap: EMG/nerve conduction studies documenting lower motor neuron involvement (fasciculations, denervation) in the presence of upper motor neuron signs (spasticity, hyperreflexia). FTD-ALS diagnosis carries major prognostic implications — median survival 2–3 years — and changes the entire hospice management plan.[7]
  • Neuroimaging patterns: MRI — frontal and anterior temporal atrophy, often asymmetric (bvFTD: predominantly frontal, bilateral or right-predominant; svPPA: anterior temporal, left > right; nfvPPA: left posterior frontal and insular). FDG-PET — frontal and anterior temporal hypometabolism, more sensitive than structural MRI early. DaT-SPECT — normal or near-normal in bvFTD and PPA (helps distinguish from Lewy body dementia).[8]
  • Genetic testing: C9orf72 repeat expansion, GRN mutations (plasma progranulin level is a useful screening biomarker), MAPT mutations, TARDBP, FUS. Genetic testing in all FTD patients under 65 and all cases with family history is clinically indicated. The hospice clinician must document the genetic testing result and facilitate genetic counseling referral for adult children at the first visit if a pathogenic mutation has been identified.[4]
What to Look for in Hospice Records
  • FTD subtype: bvFTD, svPPA, nfvPPA, or FTD-ALS — each subtype has a distinct trajectory, symptom burden, and management approach. The subtype determines the care plan.
  • Genetic testing result: C9orf72, GRN, MAPT, or other identified mutation. Has genetic counseling been offered to adult children? If not, this is a first-visit obligation.
  • Prior psychiatric diagnoses revised to FTD: Document the diagnostic odyssey — misdiagnosis as bipolar disorder, depression, personality disorder, or schizophrenia is common and shapes the family's grief and trust in the medical system.
  • Legal or criminal record from pre-diagnosis disinhibition: Shoplifting, financial misconduct, sexual inappropriateness, or aggressive behavior before diagnosis. This affects the family's grief, their legal situation, and their community standing.
  • Current behavioral medication regimen: Is the patient on SSRIs/trazodone (evidence-based for bvFTD) or primarily on antipsychotics (suboptimal in bvFTD)? Assess for rationalization at enrollment.
  • Communication method in PPA: AAC device type, current aphasia severity, caregiver proficiency with communication system.
  • ALS component: Respiratory function (FVC), bulbar function, NIV use, PEG status. FTD-ALS changes every aspect of the care plan.
  • Advance directive and capacity status: Has a healthcare proxy been designated? Was it executed while the patient had capacity? Is a conservatorship in place? This is the most time-sensitive assessment in FTD.
  • Financial and legal decision-making: Power of attorney, guardianship, ongoing financial or legal proceedings, Social Security Disability status.
  • Caregiver status: Who is providing care, what is their capacity, what is the state of the family system — the caregiver of a working-age FTD patient is often themselves still working age with dependent children and no preparation for this role.

💡 For families

💡 Para las familias

The diagnostic testing for frontotemporal dementia — the brain scans, the neuropsychological testing, the genetic blood tests — is almost always complete before hospice enrollment. You do not need to go through more testing. What matters now is that the hospice team understands your person's specific type of FTD, what medications are helping, how your person communicates, and what the genetic results mean for your family. If genetic testing was done and a mutation was found, your hospice team will help connect your adult children with a genetic counselor. This is important and time-sensitive — please do not delay this conversation.

Las pruebas diagnósticas para la demencia frontotemporal — las imágenes cerebrales, las pruebas neuropsicológicas, los análisis genéticos — casi siempre están completas antes del ingreso en hospicio. No necesitan más pruebas. Lo que importa ahora es que el equipo de hospicio entienda el tipo específico de DFT de su ser querido y lo que los resultados genéticos significan para su familia.

S03Everyone

Causes & Risk Factors

Molecular pathology, genetic causes, and the urgent genetic counseling obligation. This section answers "why did this happen?" and identifies who else in the family may be at risk.

Molecular Pathology
  • FTLD-tau (~45% of FTD cases): Abnormal accumulation of hyperphosphorylated tau protein. Includes Pick's disease, corticobasal degeneration, progressive supranuclear palsy, and familial FTD from MAPT mutations. The tau pathology in FTD is distinct from Alzheimer's neurofibrillary tangles in isoform composition and anatomical distribution — they are different diseases at the molecular level despite both involving tau.[9]
  • FTLD-TDP (~50% of FTD cases): Abnormal cytoplasmic inclusions of TDP-43, a ubiquitous RNA-binding protein. When mislocalised from the nucleus to the cytoplasm, TDP-43 disrupts RNA processing and causes neuronal death. Includes most cases of FTD-ALS, most GRN mutation cases, and most C9orf72 cases. The TDP-43 pathology in FTD and ALS is the same molecular entity — this explains the clinical overlap between the two diseases.[10]
  • FTLD-FUS (~5% of FTD cases): Rare. Associated with FUS gene mutations and some cases of basophilic inclusion body disease and neuronal intermediate filament inclusion disease. Often younger onset and rapidly progressive.[11]
Genetic Causes
  • C9orf72 repeat expansion: The most common genetic cause of both FTD and ALS globally. Autosomal dominant; high but incomplete penetrance; phenotypic variability is wide — carriers may develop pure FTD, pure ALS, or FTD-ALS. Psychiatric features including psychosis may be prominent. Tested by blood test. Adult children have 50% inheritance probability.[12]
  • GRN (progranulin) mutations: Autosomal dominant loss-of-function mutations. Progranulin is a neurotrophic factor; haploinsufficiency causes FTD. Plasma progranulin level below 60–80 ng/mL is a useful screening biomarker. bvFTD phenotype most common. Age of onset is variable even within families. Progranulin replacement therapy is in clinical trials — relevant for presymptomatic carriers.[13]
  • MAPT mutations: Autosomal dominant; penetrance approaches 100%. Phenotype includes bvFTD, Parkinsonism, and FTD-Parkinsonism linked to chromosome 17. Age of onset is more predictable within families than GRN. Adult children have 50% inheritance probability. Genetic counseling is mandatory.[14]
  • Sporadic risk factors: Age within the FTD range; positive family history in a first-degree relative without identified mutation (increases risk ~3-fold); male sex (bvFTD is more common in men; PPA variants are more evenly distributed); head trauma has been suggested but causality is not established.[1]

❤️ For families: "Why did this happen?"

Frontotemporal dementia was not caused by something your person did or did not do. It was not caused by stress, diet, lifestyle, or any decision. In some families, FTD is caused by a gene mutation that was inherited — this is no one's fault. In other families, the disease occurs without any known genetic cause and the honest answer is that science does not yet fully understand why. What we do know is that the personality changes, the behavioral symptoms, the things your person said or did that were hurtful or embarrassing — those were caused by the disease destroying the front of the brain, not by a choice. This disease took something from your family that cannot be returned. The hospice team is here to help you carry what remains.

⚕ Clinician note: Genetic counseling — the most urgent referral in FTD

Any patient with FTD and a known pathogenic mutation in C9orf72, GRN, or MAPT has adult children and siblings who carry a 50% probability of inheriting a fully penetrant fatal neurodegenerative disease. This is the same magnitude of genetic risk as familial prion disease. The genetic counseling referral belongs at the first hospice visit without exception. The counseling must cover: inheritance probability, availability of predictive genetic testing, psychological implications of testing and not testing, current absence of disease-modifying therapy (though trials are ongoing for GRN and C9orf72), reproductive planning, and connection to the AFTD and the ALLFTD consortium which offers longitudinal surveillance and trial access for presymptomatic carriers. An adult child who learns they carry a C9orf72 expansion today can enroll in a prevention trial tomorrow. The referral takes five minutes. Its consequences for a family can be life-altering. Disparity note: FTD research has been conducted predominantly in white, educated, English-speaking populations. Behavioral variant FTD in patients from cultures with different norms around social behavior may present differently and be misinterpreted. The financial devastation of FTD falls disproportionately on families without private disability insurance, without legal planning before capacity was lost, and without financial reserves to absorb the loss of a working-age breadwinner's income.[4]

S04ClinicianEveryone

Treatments & Procedures

There is no disease-modifying therapy for any FTD variant. Everything the hospice clinician does is focused on behavioral symptom management, communication support, respiratory comfort in FTD-ALS, and quality of remaining time.

There is no approved disease-modifying therapy for any form of frontotemporal dementia. Clinical trials of progranulin replacement therapy (for GRN carriers), antisense oligonucleotides targeting C9orf72 repeat expansion, and tau-targeted therapies are in development and represent the most promising research directions — but these are relevant to presymptomatic carriers in the patient's family, not to the patient at hospice enrollment. The hospice clinician must be prepared to say clearly: "There is no treatment that changes the course of frontotemporal dementia. Everything we can do is focused on comfort and quality of the remaining time." For patients with familial FTD due to GRN or C9orf72 mutations, connection to a trial center may be relevant for adult children who are presymptomatic mutation carriers — this is a separate and critically important conversation from the patient's own care.[15]

Behavioral Symptom Management
  • SSRIs — first-line for bvFTD: Sertraline 50–200 mg or citalopram 20–40 mg. The most evidence-supported pharmacological agents for behavioral symptoms in bvFTD. Reduce disinhibition, compulsive behavior, and irritability. Behavioral benefit often appears within weeks. Sertraline is preferred for its lower drug interaction profile. These are the medications to reach for first — not antipsychotics.[16]
  • Trazodone 50–300 mg: The best evidence base for nighttime agitation and sleep dysregulation in bvFTD specifically. Also effective for daytime behavioral symptoms at lower doses (50–100 mg TID). Use the sedation therapeutically for nighttime behavioral disturbance. Available in liquid for PEG administration.[17]
  • Antipsychotics — second-line only: FTD does not carry the Lewy body neuroleptic sensitivity risk, but antipsychotics are minimally effective for bvFTD behavioral symptoms and add significant side effect burden (extrapyramidal effects, metabolic syndrome, sedation). Quetiapine at low doses may provide some benefit for severe agitation when SSRIs are insufficient. Haloperidol and typical antipsychotics should be avoided. The clinical principle: SSRIs first, antipsychotics only after SSRI optimization.[18]
  • Cholinesterase inhibitors — not recommended in bvFTD: The cholinergic deficit that makes these drugs effective in Alzheimer's and LBD is not the primary neurochemical deficit in bvFTD. No benefit demonstrated; may worsen behavioral symptoms. Do not initiate. If inherited from prior prescription, reassess and deprescribe.[19]
  • Memantine — not recommended: No benefit demonstrated in FTD clinical trials. Potential for worsening behavioral symptoms. Reassess and deprescribe if on the medication list.[20]
Communication & Supportive Interventions
  • AAC devices in PPA variants: Speech generating devices, communication boards, and eye-gaze systems are the primary therapeutic intervention in nfvPPA and svPPA. Initiated early in the disease when language is declining. At advanced stage, the established communication system must be continued and all caregivers — including hospice aides and volunteers — must be trained on its use. The PPA patient with a device that no one around them knows how to use is effectively silenced.[21]
  • Speech-language pathology: The most important discipline in PPA management throughout the disease course. Ongoing assessment of swallowing safety, communication strategy adaptation, and caregiver training.
  • NIV/BiPAP in FTD-ALS: For respiratory muscle weakness from the ALS component. Improves comfort by relieving dyspnea from diaphragmatic weakness. Continue in hospice if providing comfort benefit. The decision to discontinue NIV must be made explicitly with the patient or surrogate — withdrawal will precipitate respiratory crisis and requires immediate comfort medication management with midazolam and morphine at the bedside.[22]
  • Riluzole in FTD-ALS: The only FDA-approved disease-modifying therapy for ALS; modest survival benefit (~2–3 months). May be continued if within the disease course where it was initiated. At advanced stage, reassess whether continuation aligns with comfort goals.[23]
  • PEG considerations in FTD-ALS: In ALS without dementia, PEG is standard care. In FTD-ALS, the dementia component changes the capacity and values-based dimensions of this decision. The PEG tube decision must be explicit and values-based. In bvFTD without ALS, the evidence base is the same as other advanced dementias: no survival benefit from tube feeding.
  • Dysphagia management: Modified texture, positioned feeding, aspiration precautions, comfort-directed antibiotic management of aspiration pneumonia. In bvFTD, hyperorality may drive continued oral intake even at advanced stage — hand-feeding remains appropriate and is often more easily maintained than in Alzheimer's.
S05Clinician

When Therapy Makes Sense

Evidence-based criteria for initiating or continuing symptomatic therapy in FTD at hospice enrollment. In a disease with no disease-modifying treatment, "therapy that makes sense" means every intervention that reduces suffering and protects the family.

In frontotemporal dementia there is no disease-directed therapy to continue or discontinue — the question is not about chemotherapy or targeted agents. The question is about which symptomatic and supportive interventions must be initiated, optimized, or maintained to reduce suffering and protect the family system during the hospice enrollment period. Every item below is an active clinical intervention, not passive monitoring.[16]

  1. 01
    SSRI initiation at enrollment for bvFTD behavioral symptoms: Sertraline or trazodone are the first-line pharmacological interventions for disinhibition, compulsive behavior, irritability, and sleep dysregulation in bvFTD. If the patient arrives at hospice without an SSRI or trazodone, this is a gap in symptomatic management that must be addressed at enrollment. Trazodone has the strongest evidence base for bvFTD behavioral symptoms across multiple domains including disinhibition and nighttime agitation. Start trazodone 50 mg at bedtime; titrate to behavioral effect. Add sertraline 50 mg daily if behavioral benefit is insufficient. This is not optional — it is the evidence-based standard of care.[17]
  2. 02
    Advance directive and legal decision-making capacity assessment — first visit, maximum urgency: FTD patients with bvFTD may have preserved memory and conversational capacity well into the disease while having severely impaired judgment and decision-making capacity. The legal and clinical question of decision-making capacity in bvFTD is one of the most complex in medicine. If any residual capacity exists for specific decisions, those decisions must be documented immediately. The hospice clinician who delays this assessment by one visit may find the window has closed. If no power of attorney exists and the patient can no longer execute one, a healthcare attorney consultation and conservatorship proceedings may be necessary. Do not leave the first visit without documenting capacity status and advance directive completion or the specific barriers to completion.[24]
  3. 03
    Genetic counseling referral for adult children in confirmed familial FTD — first visit: This is the same magnitude of obligation as in familial prion disease. If a pathogenic mutation in C9orf72, GRN, or MAPT has been identified, every adult child and sibling has a 50% probability of carrying the mutation. Make the referral call or write the order before you leave the first visit. The AFTD maintains a list of FTD specialist centers with genetic counseling expertise. The ALLFTD consortium provides trial access for presymptomatic carriers. Document the referral. This takes five minutes and its consequences for a family can be life-altering.[4]
  4. 04
    AAC device maintenance and caregiver training in PPA variants: The AAC device or communication system established by speech-language pathology must be maintained and all caregivers — including hospice aides, volunteers, and family members — must be trained on its use. The PPA patient who has a communication device but whose caregivers do not know how to use it is effectively silenced. Schedule a training session within the first week. Assess device functionality and battery status at every visit.[21]
  5. 05
    Social work engagement for financial and legal crisis management: The family of an FTD patient is almost certainly experiencing simultaneous financial crisis, legal complexity, and caregiver burden that exceed the scope of standard hospice social work but require immediate triage and referral. Social Security Disability applications, healthcare proxy documentation, estate planning with incapacity, mortgage default, housing instability, and caregiver employment crisis are all active issues. The hospice social worker must perform a comprehensive needs assessment at enrollment and connect the family with community legal aid, financial counseling, and the AFTD caregiver support network.[25]
  6. 06
    NIV continuation in FTD-ALS if providing comfort: The decision to continue NIV is based on whether it is relieving dyspnea. If the patient tolerates the mask and demonstrates comfort improvement, NIV is a comfort intervention and should continue. The withdrawal decision must be explicit, planned, and discussed with the family before the clinical moment arrives. Have midazolam and morphine at the bedside before any withdrawal conversation becomes urgent.[22]
  7. 07
    Pain assessment with PAINAD in nonverbal patients: The bvFTD patient who cannot communicate may be experiencing pain expressed as behavioral agitation. Assess with the PAINAD scale before escalating psychiatric medications for behavioral symptoms. The agitated patient who quiets with acetaminophen 1000 mg was in pain, not in behavioral crisis. Screen for pain at every visit before attributing behavioral changes to disease progression.[26]
  8. 08
    Aspiration pneumonia management — comfort-directed antibiotics: Same framework as other advanced dementias. The conversation about whether to treat aspiration pneumonia with antibiotics must happen at enrollment, before the first pneumonia — not during it. Document the family's decision and the clinical rationale. In bvFTD with hyperorality, aspiration risk is ongoing and predictable.
S06Clinician

When It Doesn't

Knowing when an intervention stops helping is not clinical failure. It is the most important clinical skill in frontotemporal dementia — a disease where the wrong medications are prescribed more often than the right ones.

FTD patients arrive at hospice with medication lists shaped by years of misdiagnosis. Cholinesterase inhibitors prescribed as if this were Alzheimer's. Memantine added reflexively. Antipsychotics escalated because the disinhibition was interpreted as psychosis. Every medication that is not helping is a medication that adds side effects, drug interactions, and pill burden to a patient who is already dying. The hospice enrollment visit is the moment to rationalize the medication regimen toward the evidence — SSRIs and trazodone for behavioral symptoms, deprescription of everything that was never appropriate for this disease.[19]

  1. 01
    Cholinesterase inhibitors in bvFTD — deprescribe: Donepezil, rivastigmine, and galantamine are not only ineffective in bvFTD — they may worsen behavioral symptoms by increasing cholinergic tone in a brain where the primary pathology is not cholinergic. If any of these medications are on the active medication list and the diagnosis is bvFTD, reassess with the attending physician and deprescribe with appropriate taper. The evidence is clear: no benefit, potential harm.[19]
  2. 02
    Memantine in FTD — deprescribe: Same framework. No benefit demonstrated in FTD clinical trials. Potential for worsening behavioral symptoms. Reassess and deprescribe. The family may need reassurance that stopping this medication is not "giving up" — it is removing a medication that was never effective for this disease.[20]
  3. 03
    High-dose antipsychotics for behavioral disinhibition — reassess and reduce: The disinhibited behavior of bvFTD is neurologically driven by frontal lobe dysfunction and serotonergic deficit. It does not respond to antipsychotic dose escalation the way psychosis in other conditions does. Escalating antipsychotic doses adds extrapyramidal effects, metabolic burden, and sedation without proportionate behavioral benefit. SSRIs and trazodone are the effective agents. If the patient is on high-dose antipsychotics without trazodone or an SSRI, rationalize the regimen: initiate trazodone and sertraline, then gradually reduce the antipsychotic with close behavioral monitoring. Do not exceed moderate quetiapine doses without clear documentation that the behavioral target is responding.[18]
  4. 04
    Aggressive diagnostic imaging for behavioral changes during enrolled hospice period: Once bvFTD is established, new behavioral changes are disease progression — not new diagnoses requiring imaging. The family alarmed by a new behavioral symptom should receive a prompt clinical visit and thorough assessment, but not emergency transport for a CT scan that will not change management. Explain directly: "This change is the disease progressing, not a new problem. We are going to manage it with the tools we have, and those tools do not require a scan."[5]
  5. 05
    Riluzole in FTD-ALS at very advanced stage: When comfort is the exclusive goal and remaining prognosis is weeks, reassess whether riluzole is providing any comfort benefit. Riluzole's modest survival benefit (~2–3 months) was demonstrated in earlier-stage ALS. At weeks of remaining prognosis, medication burden reduction is appropriate. Discuss with the family and attending physician. Document the clinical rationale for continuation or discontinuation.[23]
  6. 06
    NIV withdrawal when no longer providing comfort: The decision to withdraw NIV in FTD-ALS must be treated as a major clinical event. It will precipitate respiratory failure and death — typically within hours. Requirements: midazolam and morphine must be drawn, labeled, and at the bedside before withdrawal begins; the family must be prepared for what withdrawal looks like and what the comfort protocol will be; the on-call physician must be aware; the conversation must happen before the clinical moment, not during it. NIV withdrawal is not "turning off machines" — it is a planned, compassionate, medically managed transition that requires the same preparation as any critical clinical event.[22]
  7. 07
    PEG tube in advanced bvFTD without ALS component: The same evidence base as other advanced dementias: no survival benefit, no reduction in aspiration, no improvement in comfort from tube feeding. Hand-feeding for comfort is the standard. The hyperorality of bvFTD means many patients continue to eat enthusiastically even at advanced stage — hand-feeding remains appropriate and is often more easily maintained than in Alzheimer's disease because the oral drive persists.
  8. 08
    Burdensome legal proceedings that do not change management: The family in the middle of a conservatorship proceeding, financial guardianship case, or criminal case resolution involving a hospice-enrolled patient needs clinical support and documentation. But the hospice team should assess whether each legal demand on the patient's time and energy is proportionate to the remaining prognosis. Court-ordered capacity evaluations, depositions, and hearings that consume the patient's remaining functional hours and the family's remaining emotional reserves may need clinical advocacy to defer or dismiss. Document the clinical assessment of prognosis and functional status to support the family's legal counsel.

📋 Clinician note

The most common pharmacological error in FTD hospice is inheriting an Alzheimer's-oriented medication regimen — cholinesterase inhibitors, memantine, antipsychotics as first-line for behavior — and continuing it without reassessment. The enrollment visit is the intervention point. Review every medication against the FTD evidence base. The patient who arrives on donepezil, memantine, and olanzapine but not on trazodone or sertraline has a medication regimen that was built for a different disease. Rationalize it. Document the evidence basis. The behavioral improvement from switching to an SSRI/trazodone-first approach can be substantial — and the side effect reduction from deprescribing inappropriate medications can be immediate.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches for FTD. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Trazodone for bvFTD Behavioral Symptoms
Grade B
50–300 mg PO at bedtime; or 50–100 mg TID for daytime behavioral symptoms. Titrate from 50 mg every 3–5 days. Liquid suspension available for PEG.
The single most evidence-supported pharmacological intervention specific to bvFTD. Lebert et al. (2004) demonstrated significant reduction in agitation, disinhibition, and irritability in a double-blind RCT. Multiple subsequent case series confirm efficacy for sleep dysregulation, nighttime behavioral disturbance, and daytime agitation. The serotonergic mechanism addresses the serotonin deficit that drives behavioral dysregulation in FTD. Favorable side effect profile compared to antipsychotics — less extrapyramidal risk, less metabolic effect, less sedation at therapeutic doses. The clinician who inherits a bvFTD patient on multiple antipsychotics without trazodone in the regimen has an immediate opportunity to rationalize the behavioral regimen. Do not stop abruptly — taper over 1–2 weeks.[27]
SSRI Therapy for Disinhibition & Compulsive Behavior
Grade B
Sertraline 50–200 mg PO daily (preferred); Citalopram 20–40 mg PO daily (alternative). Start low, titrate to behavioral effect over 4–6 weeks.
Sertraline and citalopram have evidence from case series and small randomized controlled trials for reduction of disinhibition, compulsive behavior, and perseverative symptoms in bvFTD. The serotonergic deficit in FTD contributes directly to the impulsivity and behavioral dyscontrol that are the disease's most socially disruptive features. SSRIs must be the first-line pharmacological approach for behavioral symptoms in bvFTD — before antipsychotics, before benzodiazepines. Sertraline is preferred given its lower CYP interaction profile. Communicate to families that onset of behavioral benefit may take 4–6 weeks; this expectation management prevents premature discontinuation. Liquid formulations available for PEG administration.[28]
AAC for Primary Progressive Aphasia
Grade B
Speech-language pathology assessment at enrollment. Low-tech (picture boards, communication books) to high-tech (tablet-based AAC apps). Train ALL caregivers including hospice aides and volunteers.
Augmentative and alternative communication is the primary therapeutic intervention in PPA variants and the single most impactful non-pharmacological intervention in FTD language variants. The PPA patient who has a communication device but whose caregivers do not know how to use it is effectively silenced. AAC systems must be matched to the specific PPA variant — svPPA patients retain grammatical structure and benefit from word-finding support; nfvPPA patients lose grammatical fluency and need phrase-based systems. Multi-modal approaches (combining gesture, written, and device-based communication) provide the most robust communication maintenance. Introduce AAC early in the language decline trajectory while the patient can participate in system customization. Evidence from multiple clinical series demonstrates maintained communication and reduced behavioral agitation when AAC is implemented consistently.[29]
Structured Environmental Modification
Grade B
Home safety assessment at enrollment. Structured daily routine posted visually. Locked cabinets for medications, finances, car keys. Simplified environment with reduced stimulation.
Environmental modification is the single most effective non-pharmacological behavioral intervention in bvFTD. Structured routines reduce agitation and behavioral disturbance more effectively than dose escalation of any medication. Key elements: visual daily schedules posted at eye level, consistent meal times and activity sequences, removal of environmental triggers for compulsive behavior, locked access to finances and car keys, simplified visual environment with reduced clutter and noise. The bvFTD patient's executive dysfunction means they cannot self-regulate in an unstructured environment — the environment must provide the structure the frontal lobes no longer can. Multiple observational studies demonstrate reduced behavioral incidents, reduced caregiver distress, and reduced need for pharmacological intervention when environmental modification is implemented systematically. The hospice aide who maintains the routine is providing a therapeutic intervention as important as any medication.[30]
Music Therapy
Grade B
Individualized music sessions 20–30 minutes, 2–3 times weekly. Preferred music identified with family input. Live or recorded; consistent timing within daily routine.
Music therapy has demonstrated benefit for reducing agitation, improving mood, and facilitating social engagement in FTD across multiple observational studies. Musical memory and emotional responsiveness to music are preserved longer than language or social cognition in most FTD variants — patients who cannot speak or follow social cues may sing familiar songs, tap rhythms, and show emotional engagement during music. In PPA variants specifically, music therapy may support residual communication capacity and reduce frustration-driven agitation. Personalized playlists based on the patient's pre-illness musical preferences are more effective than generic selections. Music therapy also provides structured, predictable activity that supports the environmental modification approach. Certified music therapists can be engaged through hospice volunteer coordination where available; family-delivered music is effective when guided by therapeutic principles.[31]
Weighted Blankets & Deep Pressure Stimulation
Grade C
Weighted blanket 10–15 lbs (approximately 10% of body weight). Use during rest periods and at bedtime. Supervise in patients with ALS component or respiratory compromise.
Deep pressure stimulation through weighted blankets has limited but promising clinical evidence for reducing agitation and improving sleep quality in dementia populations. The mechanism involves proprioceptive calming and autonomic nervous system regulation. Small case series in FTD specifically suggest benefit for nighttime restlessness and daytime agitation when combined with structured environmental approaches. Safety consideration: in FTD-ALS patients with respiratory compromise, weighted blankets on the chest may exacerbate dyspnea — use on lower body only or avoid if FVC is declining. Not a substitute for pharmacological management of severe behavioral agitation, but a useful adjunct with essentially no risk in appropriate patients.[32]
Doll Therapy / Simulated Presence
Grade C
Soft doll or stuffed animal introduced without infantilization. Observe patient response. Maintain if calming; remove if distressing. Combine with structured routine.
Doll therapy and simulated presence interventions have evidence in advanced dementia for reducing agitation, providing comfort, and supporting attachment needs when social cognition is severely impaired. In bvFTD specifically, the perseverative and ritualistic behavioral pattern may lead to strong attachment to comfort objects. Case reports and small series suggest benefit for reducing wandering, repetitive vocalizations, and agitation in late-stage bvFTD. Requires careful family education — explain the neurological basis of the attachment response and frame the intervention as comfort-focused, not infantilizing. Some families find this distressing; their values must be respected. Cultural sensitivity is essential. Most appropriate in late-stage disease when other behavioral interventions have been maximized.[33]
Cannabinoids for Agitation & Appetite
Grade D
Dronabinol 2.5 mg PO BID (FDA-approved for appetite). CBD oil: no standardized dose; variable product quality. State legality varies.
Cannabinoid use in FTD is supported only at the level of case reports and expert opinion. Dronabinol (synthetic THC) has FDA approval for appetite stimulation and may address the weight loss seen in some FTD patients who have altered eating patterns. Case reports suggest possible benefit for agitation in advanced dementia, but no FTD-specific controlled trials exist. CBD products vary enormously in quality, purity, and dosing; regulatory oversight is minimal. Safety considerations in FTD: potential for paradoxical agitation (especially THC-dominant products), drug interactions with sertraline and trazodone via CYP3A4 and CYP2D6, and the impulsivity of bvFTD patients who may overconsume edible products. If families request cannabinoid use, engage the conversation without judgment; recommend pharmaceutical-grade dronabinol over unregulated products; and monitor for drug interactions and behavioral changes.[34]
S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to FTD. Patients will use supplements — this section helps you have the right conversation.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"FTD families ask about supplements differently than other dementia families. They've usually been through years of misdiagnosis and are desperate for anything that might help. The conversation is: 'I hear you. There is no supplement that changes the course of this disease. But I want to know everything you're giving, because some of these interact with the trazodone and sertraline that are actually working. And with your person's impulsivity, every bottle in this house needs to be locked up — not because they'll abuse it, but because the frontal lobes that say stop are the ones the disease took first.'"
— Waldo, NP

⚠ FTD-Specific Supplement Safety

Frontotemporal dementia has no disease-modifying treatment. The supplement evaluation in FTD has two critical safety considerations: (1) Serotonergic interactions — the SSRIs and trazodone that are the backbone of bvFTD behavioral management are serotonergic agents; any supplement with serotonergic activity adds serotonin syndrome risk. (2) Seizure threshold — FTD carries higher seizure prevalence than Alzheimer's disease, particularly in C9orf72 expansion carriers; supplements that lower seizure threshold are contraindicated. Additionally, the impulsivity and hyperorality of bvFTD mean the patient may consume supplements in unpredictable quantities — secure all supplements and medications away from the patient's independent access. The principle is simplicity and safety — every addition must be evaluated against the active serotonergic and antiseizure medication regimen.[35]

Herb / Supplement Evidence Grade Typical Dose Potential Benefit ⚠ Interactions / Contraindications
Melatonin Grade B 3–10 mg PO at bedtime; liquid formulation available for dysphagia/PEG Sleep dysregulation and nighttime behavioral disturbance. Circadian disruption from frontal and hypothalamic involvement is an early feature of bvFTD. Melatonin is the safest first-line sleep intervention in FTD. Multiple studies in dementia populations support efficacy.[36] No serotonergic activity. No seizure threshold effect. No clinically significant interaction with sertraline, trazodone, or quetiapine at standard doses. Safe in combination with SSRI-based behavioral regimens. May cause morning drowsiness at higher doses.
Omega-3 Fatty Acids (EPA/DHA) Grade C 1–2 g EPA+DHA daily; liquid or soft gel; administer with food Potential neuroprotective and anti-inflammatory properties. Limited but suggestive evidence for mood stabilization in neurodegenerative populations. May support general brain health. No evidence for disease modification in FTD specifically.[37] Mild antiplatelet effect at high doses — assess if patient is on anticoagulation. GI upset (fishy taste, loose stools) may be poorly tolerated. No serotonergic interaction. No seizure threshold effect. Low risk; reasonable to continue if patient/family values it.
Vitamin E Grade C 400–800 IU daily; do not exceed 1000 IU daily Antioxidant neuroprotection. One RCT showed modest slowing of functional decline in moderate Alzheimer's disease (Dysken 2014). No FTD-specific trial data. Theoretical benefit only in FTD context.[38] High-dose vitamin E (>1000 IU/day) associated with increased all-cause mortality in meta-analyses. Anticoagulant potentiation at high doses. Keep dose ≤800 IU. No serotonergic interaction. No seizure threshold effect. Discontinue if bleeding risk is elevated.
Vitamin D Grade C 1000–2000 IU daily; check 25-OH vitamin D level if available Vitamin D deficiency is common in homebound FTD patients. Deficiency may exacerbate neuropsychiatric symptoms and contribute to bone loss and fall risk. Supplementation corrects deficiency and supports musculoskeletal health in a population with significant fall risk.[39] No significant drug interactions at standard doses. No serotonergic activity. No seizure threshold effect. Well tolerated. Toxicity only at very high doses (>10,000 IU daily sustained). One of the safest supplements in the FTD population.
Coconut Oil / MCT Oil Grade D 1–2 tablespoons daily with food; begin at lower doses to assess GI tolerance Proposed ketone body production as alternative brain energy source. Theoretical benefit based on brain glucose hypometabolism in neurodegenerative disease. No controlled trial evidence in FTD. Anecdotal reports only.[40] GI disturbance (diarrhea, cramping) common at initiation. High caloric density may be beneficial for underweight patients or problematic for overweight patients with hyperorality. No serotonergic interaction. No seizure threshold effect. Aspiration risk with liquid oil in patients with dysphagia — use MCT powder formulation if swallowing is impaired.
Ginkgo biloba Grade D 120–240 mg standardized extract daily in divided doses Theoretical cerebral blood flow enhancement and antioxidant neuroprotection. Modest evidence in Alzheimer's disease from some trials (GEM study was negative for prevention). No FTD-specific evidence.[41] Antiplatelet activity — clinically relevant if patient is on anticoagulants or has bleeding risk. Potential CYP interaction with some medications. Seizure risk: case reports of seizures with ginkgo — use with extreme caution in C9orf72 carriers or patients with seizure history. No serotonergic interaction at standard doses. Marginal benefit-to-risk ratio in FTD population.
🚫 Avoid in FTD
  • St. John's Wort (Hypericum perforatum): Potent serotonergic activity and CYP3A4/2C9 induction. Direct serotonin syndrome risk when combined with trazodone or sertraline — the backbone medications of bvFTD behavioral management. Also lowers seizure threshold. Absolutely contraindicated in FTD patients on SSRI/trazodone regimens.[42]
  • High-dose 5-HTP (5-Hydroxytryptophan): Serotonin precursor. Additive serotonergic effect with SSRIs and trazodone — serotonin syndrome risk. Even moderate doses (50–100 mg) in combination with sertraline or trazodone can produce clinically significant serotonergic excess. Do not use in any patient on serotonergic medications.
  • Kava (Piper methysticum): Hepatotoxic potential. GABAergic mechanism potentiates sedation from trazodone, quetiapine, and benzodiazepines. May lower seizure threshold. Unpredictable sedation when combined with the FTD behavioral medication regimen. Contraindicated.
  • Ginseng (Panax ginseng): CNS stimulant properties may exacerbate agitation, disinhibition, and sleep dysregulation in bvFTD. Potential interaction with antidiabetic and anticoagulant medications. No evidence of benefit in FTD. The stimulant effect is the opposite of what the bvFTD behavioral regimen is designed to achieve.
  • Ephedra (Ma huang): Sympathomimetic stimulant. Exacerbates agitation, raises blood pressure, lowers seizure threshold. Dangerous in combination with any psychotropic medication. Banned by FDA in dietary supplements but still available in some herbal preparations. Contraindicated in all FTD patients.
S09Everyone

Timeline Guide

A guide, not a prediction. The FTD timeline is shaped by variant type, genetic status, and ALS overlap. bvFTD median 6–11 years from onset; FTD-ALS median 2–3 years — the most rapidly fatal variant.

The FTD timeline is distinguished from all other dementias by three features: (1) working-age onset that intersects with employment, active parenting, and financial responsibility; (2) behavioral changes that precede diagnosis by years, causing professional, legal, financial, and relational damage before anyone understands what is happening; and (3) variant-specific trajectories — FTD-ALS compresses the entire trajectory to 2–3 years, while bvFTD may span a decade. The hospice clinician must identify the variant trajectory at enrollment and frame the timeline accordingly.[27]

📊 Variant Trajectory Summary

  • bvFTD: Median 6–11 years from symptom onset. Hospice enrollment typically in final 1–2 years. Slow behavioral escalation with progressive loss of self-care, mobility, and ultimately swallowing.
  • svPPA: Median 8–12 years. Language loss progresses to mutism; behavioral symptoms emerge later. Relatively preserved motor function until late disease.
  • nfvPPA: Median 7–10 years. May evolve into corticobasal syndrome or progressive supranuclear palsy phenotype with parkinsonism and falls.
  • FTD-ALS: Median 2–3 years from symptom onset. The most rapidly fatal variant. Respiratory failure is the primary cause of death. Hospice enrollment may occur within months of diagnosis.[43]
YRS
Pre-Diagnosis Behavioral Changes (Years Before Diagnosis)
  • Personality transformation: Social disinhibition, loss of empathy, apathy, or compulsive behaviors emerge gradually — the family notices something is wrong but cannot name it; the person may be fired, arrested, or divorced before any medical evaluation occurs
  • Professional and financial collapse: Poor financial decisions, professional misconduct, inappropriate workplace behavior — the family compensates, covers, and absorbs losses that may amount to hundreds of thousands of dollars before diagnosis
  • Diagnostic odyssey: Multiple psychiatric evaluations; misdiagnosis as depression, bipolar disorder, personality disorder, or midlife crisis; average diagnostic delay 3–4 years from first symptoms to correct FTD diagnosis[44]
  • Legal consequences: Disinhibited behavior may result in criminal charges (shoplifting, public indecency, aggressive behavior) — the family now carries legal burden alongside medical uncertainty
  • Relational devastation: Marital conflict, alienation of children, loss of friendships and community connections — the family system has been under extreme stress for years before anyone names the disease
  • The hospice question that opens everything: "Can you tell me what the last few years were like, before the diagnosis was made?" — this question provides the most important contextual information of the entire enrollment
MOS–
WKS
Diagnosis to Hospice Eligibility — Active Decline
  • Diagnosis confirmed: Family begins to understand that the behavioral changes were neurological, not psychiatric or characterological — relief mixed with grief as the trajectory becomes clear
  • Behavioral escalation: In bvFTD, disinhibition and compulsive behaviors may worsen; in PPA, language deteriorates toward mutism; in FTD-ALS, motor and respiratory symptoms accelerate rapidly
  • Functional decline: Progressive loss of instrumental ADLs (finances, driving, cooking) followed by basic ADLs (dressing, bathing, toileting); increasing supervision needs; eventual 24-hour care requirement[45]
  • Legal and financial crisis management: Power of attorney, guardianship proceedings if decision-making capacity is already lost, disability applications, family medical leave — all of these hit simultaneously in a family already in crisis
  • Medication optimization: SSRI/trazodone behavioral regimen should be initiated and titrated during this phase; communication systems established for PPA variants; NIV initiated for FTD-ALS respiratory decline
WKS–
MOS
Hospice Enrollment — Stabilization & Adjustment
  • Enrollment criteria met: Functional status equivalent to FAST 7C or beyond (dependent in all ADLs, minimal verbal output, inability to ambulate independently) plus qualifying comorbid conditions; ALS component significantly accelerates eligibility[46]
  • First visit priorities: Advance directive completion (urgent — capacity may be minimal), genetic counseling referral for adult children, behavioral medication rationalization (SSRI/trazodone first), communication system assessment in PPA, NIV status and withdrawal planning in FTD-ALS
  • Behavioral regimen stabilization: Trazodone and sertraline titrated to optimal behavioral effect; environmental modifications implemented; daily routine structured and communicated to all caregivers including aides
  • Caregiver assessment and support: The caregiver has been in crisis for years — screen for burnout, depression, financial strain, and social isolation; refer to AFTD caregiver support resources; the younger spouse caregiver needs fundamentally different support than the elderly spouse in Alzheimer's care
  • Safety plan for disinhibition: Document specific behavioral risks; establish protocol for managing public or domestic safety incidents; ensure family has 24-hour hospice phone access
DAYS–
WKS
Pre-Active Dying
  • Profound functional decline: Bed-bound or chair-bound; minimal to no purposeful movement; dysphagia progresses to inability to safely swallow — PEG feeding decision may arise in FTD-ALS (discuss goals of care rather than default to placement)
  • Communication loss: In bvFTD, mutism or very limited verbal output; in PPA, complete aphasia — but auditory comprehension may persist longer than verbal production; continue speaking to the patient normally[29]
  • In FTD-ALS — respiratory decline: Increasing NIV dependence; CO2 retention; periods of air hunger when NIV is removed; the NIV withdrawal conversation must have already happened — do not have this conversation for the first time at this phase
  • Comfort medication adjustment: Transition to sublingual, buccal, or subcutaneous routes; morphine for dyspnea; midazolam available for respiratory distress; glycopyrrolate for secretions
  • Family preparation: Explicit education about what the final hours will look like; specific crisis protocols reviewed (seizure, respiratory arrest in ALS-FTD); comfort kit medications verified and demonstrated
HRS–
DAYS
Final Hours
  • Terminal respiratory pattern: Cheyne-Stokes respiration, agonal breathing, mandibular breathing; in FTD-ALS, this phase may include acute respiratory failure if NIV is withdrawn — have morphine and midazolam drawn and labeled at the bedside before withdrawal
  • Unresponsive or minimally responsive: Auditory awareness may persist — speak to the patient, not about them; families should be told that hearing is the last sense to go and that their presence and words still reach the person
  • Terminal secretions: Glycopyrrolate 0.2 mg SQ q4h PRN; reposition for postural drainage; explain to family that the sound is not choking or drowning — it is fluid in the airway of someone who is no longer swallowing
  • Seizure risk: Elevated in FTD, particularly C9orf72 carriers — levetiracetam should be continued until death; midazolam 5 mg SQ/buccal available for breakthrough seizure; family educated on seizure protocol
  • The family's specific grief: The bvFTD family may have been grieving for years — the final hours may bring relief alongside sorrow; the PPA family may grieve the loss of communication that happened years before the body dies; the FTD-ALS family may have had only months from diagnosis to death; meet each family where they are
S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for FTD. SSRI/trazodone-first behavioral management. ALS-FTD respiratory protocol. What to have in the comfort kit and what to titrate first.

⚠ FTD Medication Management — Two Simultaneous Priorities

(1) Behavioral symptom management with SSRIs and trazodone as the evidence-based first line — not antipsychotics, not cholinesterase inhibitors, not memantine. The pharmacological approach to bvFTD behavioral symptoms that is not SSRI-first is not evidence-aligned and must be reassessed at enrollment. (2) In FTD-ALS, every medication decision must account for the rapid respiratory trajectory and NIV status — the patient on NIV who is declining rapidly toward NIV withdrawal requires a fully prepared comfort medication protocol at the bedside before withdrawal is initiated.[27]

At enrollment: Assess the behavioral medication regimen and rationalize it toward SSRI/trazodone first. Assess NIV status and respiratory trajectory in FTD-ALS. Assess communication system in PPA variants. Complete the advance directive before any other clinical task if any residual capacity exists.

DrugClass / Target SymptomStarting DoseNotes / Cautions
Trazodone SARI / Behavioral agitation, disinhibition, sleep dysregulation in bvFTD 50 mg PO QHS; titrate to 300 mg. 50–100 mg TID for daytime symptoms. Liquid for PEG. The most evidence-supported pharmacological agent in bvFTD specifically. Serotonergic mechanism addresses the deficit driving behavioral dysregulation. Use the sedation therapeutically for nighttime behavioral disturbance. Do not stop abruptly — taper over 1–2 weeks. Lebert et al. 2004 RCT is the landmark evidence.[27]
Titrate every 3–5 days to behavioral effect. Monitor for orthostatic hypotension and priapism.
Sertraline SSRI / Disinhibition, compulsive behavior, irritability in bvFTD 50 mg PO daily; titrate to 200 mg. Liquid for PEG. The preferred SSRI in FTD given low drug interaction profile. Onset of behavioral benefit 4–6 weeks — communicate this to families. Most effective for reducing disinhibition and compulsive behaviors. The trazodone + sertraline combination is the evidence-based behavioral regimen in bvFTD.[28]
Monitor for GI side effects at initiation. Serotonin syndrome risk if combining with other serotonergic agents.
Quetiapine Atypical antipsychotic / Severe behavioral agitation refractory to SSRI/trazodone 12.5–25 mg PO QHS; titrate to 100–200 mg/day in divided doses Second-line after SSRI/trazodone optimization. FTD does not carry the same neuroleptic sensitivity as Lewy body dementia, but antipsychotics are minimally effective for bvFTD behavioral symptoms and add significant side effect burden. Use only when SSRI/trazodone is optimized and behavioral distress remains severe. ⚠ Caution: QTc prolongation, metabolic syndrome, extrapyramidal effects.[47]
Morphine Opioid / Pain, dyspnea (especially FTD-ALS respiratory distress) 2.5–5 mg PO/SL/SQ q4h PRN; titrate to effect First-line for dyspnea in FTD-ALS. Essential component of NIV withdrawal protocol — administer 15–30 minutes before NIV removal. Also indicated for pain assessment by PAINAD scale in non-verbal FTD patients. Concentrate (20 mg/mL) for sublingual use in late-stage dysphagia.[48]
Lorazepam Benzodiazepine / Anxiety, adjunctive agitation 0.5–1 mg PO/SL/SQ q4–6h PRN Adjunctive for anxiety component in FTD. Avoid scheduled use — paradoxical disinhibition possible in frontal lobe disease. Useful for acute situational anxiety in patients with preserved insight (early PPA, some early bvFTD). Have available in comfort kit for terminal phase.
May worsen cognitive impairment and increase fall risk. Use with caution in combination with trazodone (additive sedation).
Midazolam Benzodiazepine / Terminal agitation, respiratory distress, seizure, NIV withdrawal 2.5–5 mg SQ/buccal PRN; 1–5 mg/hr CSCI for refractory agitation Essential for NIV withdrawal protocol in FTD-ALS — have drawn and labeled at bedside before withdrawal. Also first-line for breakthrough seizure in terminal phase. Terminal agitation management when oral medications are no longer feasible. ⚠ Must be at bedside pre-drawn for FTD-ALS patients approaching NIV withdrawal.[49]
Glycopyrrolate Anticholinergic / Terminal secretions 0.2 mg SQ q4h PRN Reduces secretions without CNS effects. Preferred over hyoscine butylbromide in patients with any residual consciousness — does not cross blood-brain barrier. Start early when secretions first become audible; less effective once secretions are established.[50]
Dexamethasone Corticosteroid / Cerebral edema, appetite, anti-inflammatory 2–4 mg PO/SQ daily–BID Limited role in FTD compared to oncology. May have benefit for symptomatic cerebral edema in rapidly progressive cases. Short-term appetite stimulation. Consider for terminal phase comfort if other measures insufficient. Monitor blood glucose.
Not disease-modifying. Time-limited use. Taper if used >7 days.
Levetiracetam Antiepileptic / Seizure prophylaxis and treatment 250–500 mg PO BID; titrate to 1000–1500 mg BID. Liquid for PEG. IV available. FTD carries higher seizure prevalence than Alzheimer's disease, particularly in C9orf72 expansion carriers. Levetiracetam is preferred anticonvulsant in FTD — no hepatic metabolism, minimal drug interactions, available IV and liquid. Continue until death in patients with seizure history. Behavioral side effects (irritability, aggression) may occur — monitor in context of existing behavioral symptoms.[35]
Mirtazapine NaSSA / Depression, insomnia, appetite stimulation 7.5–15 mg PO QHS Addresses depression, insomnia, and anorexia simultaneously. More sedating at lower doses (7.5 mg) than higher doses (30 mg). Consider for FTD patients with comorbid depression and weight loss, particularly when appetite stimulation is desired. Noradrenergic/serotonergic mechanism — monitor for serotonin syndrome if combining with SSRI/trazodone regimen.
Useful as adjunct to SSRI regimen for sleep and appetite; use cautiously with trazodone (additive sedation).
Metoclopramide Prokinetic antiemetic / Nausea, gastroparesis 5–10 mg PO/SQ q6h PRN; max 30 days per FDA For nausea and gastroparesis which may occur in advanced FTD, particularly in FTD-ALS with autonomic involvement. ⚠ Caution: Extrapyramidal side effects — increased risk in patients with neurodegenerative disease. Use short-term only. Avoid in patients with existing parkinsonism (nfvPPA evolving to CBS/PSP).
Hyoscine butylbromide Anticholinergic / Terminal secretions (alternative) 20 mg SQ q4–6h PRN Alternative to glycopyrrolate for terminal secretion management. Does not cross blood-brain barrier. Useful when glycopyrrolate is unavailable. Also effective for abdominal cramping and colic in terminal phase.[50]

🌿 Symptom Management Decision Tree

Evidence-based · Hospice-adapted · FTD-specific
Select a symptom below to begin
What is the primary symptom to address?

🚨 FTD Comfort Kit Must-Haves

At the bedside before the crisis, not during it:

  • Morphine concentrate 20 mg/mL: For dyspnea and pain — sublingual in patients who cannot swallow. Essential for NIV withdrawal protocol in FTD-ALS. Dose: 5–10 mg SL q2h PRN.
  • Midazolam 5 mg/mL: Pre-drawn syringes labeled with dose. For terminal agitation, seizure, and respiratory distress during NIV withdrawal. Dose: 2.5–5 mg SQ or buccal. In FTD-ALS: have 2 syringes drawn and labeled at bedside.
  • Lorazepam 2 mg/mL: For anxiety and adjunctive agitation. Dose: 0.5–1 mg SL/SQ q4h PRN.
  • Glycopyrrolate 0.2 mg/mL: For terminal secretions. Start at first audible secretions. Dose: 0.2 mg SQ q4h PRN.
  • Levetiracetam oral solution: For seizure-prone FTD patients (especially C9orf72 carriers). Continue scheduled anticonvulsant via PEG or SL until death.
  • Haloperidol 5 mg/mL (emergency only): For catastrophic terminal agitation refractory to midazolam. Dose: 0.5–2 mg SQ. Last resort — not first line in FTD.
S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team working with FTD. The things not in the textbook — learned at the bedside over years with these families.

1
Ask about the years before the diagnosis
Not as social history collection — as clinical orientation. "Can you tell me what the last few years were like before you got this diagnosis?" opens everything: the diagnostic odyssey, the professional losses, the legal consequences, the relational damage, the financial crisis. The family who has lived through 3–4 years of inexplicable personality change and been told it was depression or a midlife crisis or a character flaw does not begin to grieve normally until someone names what actually happened. That naming, at the first hospice visit, is a clinical act. It is the most important question you will ask at enrollment.[44]
2
Genetic counseling referral — first visit, no exceptions
The genetic counseling referral for adult children with familial FTD must happen at the first visit. Call or document a referral before you leave. The AFTD maintains a list of FTD specialist centers with genetic counseling expertise. The ALLFTD consortium provides trial access for presymptomatic carriers. An adult child who learns they carry a C9orf72 expansion today can enroll in a prevention trial tomorrow. An adult child planning a pregnancy who carries a GRN mutation needs reproductive counseling now. The referral takes five minutes. Its consequences for a family can be life-altering. This is not optional clinical work — it is the same magnitude of obligation as genetic counseling in familial cancer syndromes.[51]
3
SSRI/trazodone first — rationalize the behavioral regimen at enrollment
If the patient arrives at hospice on antipsychotics without trazodone or SSRI, the pharmacological approach has not followed the evidence. Initiate trazodone 50 mg at bedtime at enrollment. Titrate to behavioral effect over the following weeks. Add sertraline 50 mg in the morning if behavioral benefit is insufficient. Use quetiapine only when SSRI/trazodone is optimized and behavioral distress remains severe. Document the evidence basis for this regimen approach. The clinician who uses trazodone skillfully in bvFTD provides more behavioral symptom relief with less side effect burden than any antipsychotic combination.[27]
4
NIV withdrawal conversation in FTD-ALS — at enrollment, not at crisis
Tell the family clearly and specifically: "There will likely come a point when the mask is no longer providing comfort, when the disease has progressed to where the ventilator support is prolonging dying rather than reducing suffering. When that point comes, we will be prepared." Then prepare: morphine and midazolam drawn and labeled at the bedside. The family who has been told this at enrollment, in calm daylight, will be able to consent to NIV withdrawal when the time comes. The family hearing it for the first time during an acute respiratory crisis at 2 AM cannot. This conversation is a clinical obligation in every FTD-ALS enrollment.[49]
5
PAINAD scale for non-verbal pain assessment
FTD patients who have lost verbal communication cannot self-report pain. The PAINAD scale (Pain Assessment in Advanced Dementia — Warden et al. 2003) assesses breathing patterns, negative vocalization, facial expression, body language, and consolability. Score ≥2 warrants a comfort trial of analgesia. Use PAINAD on every visit for non-verbal FTD patients. Assume pain is present if there is any behavioral change — agitation may be undertreated pain, not behavioral escalation requiring more antipsychotics. Treat with analgesia first, then reassess.[52]
6
PPA communication system — maintain it, train everyone on it
The AAC device or communication system established by speech-language pathology must be maintained and all caregivers — including hospice aides, volunteers, and overnight respite staff — must be trained on its use. The PPA patient who has a communication device that no one around them knows how to use is effectively silenced. Put the communication instructions on the refrigerator. Demonstrate the device to every team member who enters the home. Document the communication method in the care plan. Assume the patient understands more than they can express.[29]
7
Financial and legal crisis management at enrollment
FTD strikes in the working years. The family has often already lost the primary income, may have lost housing or retirement savings to disinhibited financial decisions, and may face guardianship proceedings if no power of attorney exists. Social work engagement is not optional — it is a first-visit priority. Connect the family with AFTD financial resources, disability benefits navigation, and local legal aid if guardianship is needed. The social worker who addresses the financial crisis is treating the family's suffering as directly as the nurse who manages pain.[53]
8
Caregiver burnout and isolation screening
The bvFTD caregiver is statistically the most burdened caregiver in all of dementia care — higher caregiver stress, higher depression rates, and higher rates of social isolation than Alzheimer's caregivers. The behavioral symptoms that define bvFTD — disinhibition, loss of empathy, socially inappropriate behavior — drive away the support network at the moment the caregiver needs it most. Screen for caregiver depression (PHQ-2) at every visit. Ask directly: "When was the last time you left this house for something other than a medical appointment?" Connect to FTD-specific support groups (AFTD). The younger spouse caregiver needs different support than the elderly Alzheimer's caregiver — they may still be parenting, employed, and carrying financial obligations.[54]
9
Younger caregiver and spouse support
FTD caregivers are often 50–60 years old, still employed, still raising children, still carrying a mortgage. They are not the 80-year-old spouse caregiver the hospice system was designed for. They need evening and weekend support availability. They need respite that accounts for the safety risks of bvFTD behavioral disinhibition — not every respite aide is prepared for a patient who may be verbally aggressive, sexually inappropriate, or attempt to leave the home. They need financial counseling. They may need couples therapy or family therapy to process the grief of a partner who is physically present but neurologically absent. Tailor the support plan to the age and life stage of the caregiver.[54]
10
The disinhibition safety plan
Disinhibited behavior in bvFTD can be physically dangerous — to the patient, to the caregiver, and to others. At enrollment, assess and document specific behavioral risks: Does the patient attempt to leave the home? Are they physically aggressive? Are there sexually inappropriate behaviors? Do they attempt to drive, use the stove, or handle sharp objects? Establish a safety plan: locked exits (with fire-safe egress), secured kitchen, car keys removed, firearm assessment and removal, behavioral de-escalation protocol. Teach the caregiver: do not confront or argue — redirect, distract, and remove the trigger. Document the safety plan in the care plan and review it with every team member who enters the home.[30]
From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"Every FTD enrollment visit, I do three things before I leave: I make the genetic counseling referral call, I start trazodone if it's not already on board, and I ask the caregiver when the last time they slept through the night was. The answer to that third question tells me more about the urgency of the care plan than any clinical assessment I could do."
— Waldo, NP · Terminal2
S12EveryoneClinician

Psychosocial & Spiritual Care

The grief of personality replacement, the shame of behavioral disinhibition, the genetic burden on adult children, and the younger-age devastation that makes FTD psychosocial care unlike any other dementia.

Frontotemporal dementia produces a category of grief that has no cultural script. The bvFTD family does not experience the gradual fading of Alzheimer's disease. They experience the replacement of their person by someone entirely different — someone who says cruel things, who has no empathy, who is disinhibited and sometimes frightening, who does not recognize the social rules that defined them. The PPA family watches their person lose the ability to speak while cognition may remain partially intact — a different and equally devastating loss. The FTD-ALS family faces a compressed timeline of 2–3 years that leaves almost no time to process anything. And all of this happens to people in their 50s and 60s, still working, still parenting, still carrying mortgages.[54]

The hospice clinician who walks into an FTD home is not walking into the end of a long illness. They are walking into the wreckage of a life interrupted. The psychosocial care must match the complexity of the devastation.

The Specific Grief of FTD
Grief of Personality Replacement (bvFTD)

The bvFTD caregiver is not grieving someone who is fading. They are grieving someone who has been replaced — by a person who is physically present but neurologically unrecognizable. The body of their spouse, parent, or partner continues to walk, eat, and speak, but the person inside is gone. This is not ambiguous loss in the traditional sense — it is the specific grief of watching your person become someone you do not know and do not like, someone who may be cruel, selfish, and frightening. The hospice chaplain who can name this — "You are not just grieving who they were; you are grieving the relationship you had, because this person here now is not the relationship you had" — provides something that cannot be given any other way.[55]

Shame and Isolation from Disinhibition

The bvFTD family is often the most socially isolated of all dementia families. The patient's behavior in public — racist comments, sexual inappropriateness, aggression, shoplifting, grabbing strangers — has driven away friends, neighbors, extended family, and faith community. The family is caregiving in complete social isolation at the moment they most need community. The hospice social worker who acknowledges this directly — "I know the things your person has been saying and doing have made it very hard to bring people into your life; that isolation is one of the most painful parts of this disease" — begins to break through the shame that keeps the caregiver silent.[54]

Younger-Age Grief: Career, Financial, Parenting

FTD strikes at 45–65 years. The caregiver may still be employed, parenting minor children, carrying a mortgage, and planning for retirement that will now never happen. The financial devastation is often catastrophic — loss of the patient's income, depletion of savings from disinhibited spending during the pre-diagnosis years, disability application battles, potential loss of health insurance. Children may be adolescents or young adults who are simultaneously losing a parent and watching the surviving parent collapse under caregiving burden. This is not the grief of old age. It is the grief of a life plan destroyed in its prime.[53]

Genetic Burden — Adult Children at 50% Risk

In familial FTD (C9orf72, GRN, MAPT), adult children carry a 50% probability of inheriting the mutation. This knowledge transforms the grief from "my parent is dying" to "I may die the same way." The existential anxiety for adult children is enormous — every forgotten word, every personality quirk, becomes a potential symptom. Genetic counseling provides structure, information, and access to presymptomatic surveillance and trials. But it also delivers devastating news to some. The hospice team must facilitate the referral while providing emotional support for whatever the results may be.[51]

FTD-ALS Compressed Timeline Grief

The FTD-ALS family may have had only months between diagnosis and hospice enrollment. There has been almost no time to process the behavioral changes, the communication losses, and now the respiratory decline happening simultaneously. The grief is compressed, layered, and overwhelming. The family is watching their person lose personality, speech, and breath at the same time. Support must be intensive, immediate, and sustained through bereavement. Early chaplaincy and social work engagement is not optional — it is the only way to provide adequate support in a timeline this compressed.[43]

Psychological Distress Screening
Caregiver Depression — Screen at Every Visit
Grade B

FTD caregiver depression rates are among the highest in all dementia caregiving — exceeding 40% in some studies. Use PHQ-2 at every visit: "Little interest or pleasure in doing things?" and "Feeling down, depressed, or hopeless?" Score ≥3 warrants full PHQ-9 and intervention.[54]

  • Caregiver depression is a clinical emergency in FTD — the isolated, burned-out caregiver is the only safety net for a patient who cannot self-protect
  • Pharmacological treatment (mirtazapine 7.5 mg QHS addresses insomnia, depression, and appetite simultaneously), therapy referral, and practical respite are all indicated
  • AFTD support groups — online and in-person — provide the only community that truly understands the FTD caregiver experience
Patient Depression & Existential Distress
Grade B
  • In PPA variants: The patient may retain insight into their language loss and experience profound grief, frustration, and depression — screen using non-verbal assessment tools if verbal screening is not possible
  • In early bvFTD: Some patients have periods of awareness that something is profoundly wrong; depression and anxiety may be present alongside the behavioral symptoms
  • In late-stage FTD: Behavioral observation (PAINAD, Dementia Mood Assessment Scale) replaces self-report; agitation may indicate undertreated depression or pain
  • Dignity therapy: Where cognition permits, structured life narrative work preserves the person's identity for their family — particularly powerful in FTD where the disease has obscured who the person was
Spiritual Assessment

FTD spiritual care operates in a unique landscape. The patient with bvFTD may have alienated their faith community through disinhibited behavior — the church they attended for decades may no longer welcome them. The spouse may feel abandoned by God for a disease that took their partner's personality but left their body. The adult child facing a 50% genetic risk may be in spiritual crisis about their own mortality decades before they expected it. Use the FICA framework (Faith/beliefs, Importance, Community, Address) — but adapt it to FTD: "Has your faith community been able to stay involved, or has the disease made that difficult?" opens the conversation about the spiritual isolation that disinhibition creates.[55]

Clinical Pearl

"In FTD, the spiritual assessment is often more about the caregiver than the patient. The bvFTD patient's capacity for spiritual reflection may be severely impaired by frontal lobe damage. But the caregiver — the spouse who is watching their partner become a stranger, the adult child who carries the genetic uncertainty — is in spiritual crisis. The chaplain who focuses on the family's spiritual suffering in FTD is often doing the most important spiritual work in the home."

  1. 01
    Ask about faith community access: "Has the disease made it hard for your family to stay connected to your church/temple/community?" Many FTD families have been effectively exiled from their faith community by the patient's behavior. Naming this loss is the first step in addressing it.[55]
  2. 02
    Chaplaincy at enrollment — for the family: In FTD, chaplaincy serves the caregiver and family as much as or more than the patient. The caregiver's existential distress, moral injury from caregiving someone who is hostile, and spiritual questioning about meaning all require professional spiritual care.
  3. 03
    Legacy work is urgent in FTD: The disease has obscured who the patient was. Structured legacy projects — photo books, recorded messages (if done before language loss), written letters — preserve the person the family knew before the disease changed them. This is both therapeutic for the family and a concrete act of resistance against the disease's erasure of identity.
  4. 04
    Genetic anxiety requires spiritual support: The adult child facing a 50% risk of the same disease is in a unique existential position. This is not generic worry about illness — it is the lived experience of watching exactly what may happen to them. Chaplaincy, genetic counseling, and psychological support form a triad for these family members.
Goals-of-Care Communication in FTD
FTD-Adapted Goals Conversation
  • "What was your person like before this disease? Tell me about them." — Establishes the person the family is grieving, not just the patient you are treating
  • "What do you think they would want if they could tell us?" — Activates substituted judgment, which is essential when the patient's current behavior may contradict their pre-illness values
  • "Given everything you've been through these past years, what matters most to you right now?" — Acknowledges the pre-diagnosis suffering and surfaces caregiver priorities
  • In FTD-ALS: "We need to talk about the breathing support specifically — I want you to be ready, not surprised." — Opens NIV withdrawal conversation
Communication Pitfalls in FTD
  • Don't blame the family for late diagnosis: The 3–4 year diagnostic delay is systemic — psychiatric misdiagnosis is the norm, not an error by the family
  • Don't minimize the behavioral history: The years of disinhibited behavior caused real damage — legal, financial, relational — that the family is still managing alongside the clinical disease
  • Don't assume the patient cannot understand: Especially in PPA, cognition may be more intact than communication suggests; speak to the patient, not around them
  • Don't conflate behavioral symptoms with the person: "That is the disease talking, not your husband" is one of the most important things you can say to a bvFTD family
  • Don't delay difficult conversations: FTD can decline rapidly; have the advance directive, NIV withdrawal, and genetic counseling conversations at the first visit
Suicidal Ideation & Hastened Death Requests

FTD creates unique risk factors for suicidal ideation — in both patients and caregivers. Patients with early bvFTD or PPA who retain partial insight may experience profound despair at their losses. Caregivers — exhausted, isolated, financially devastated, and grieving a person who is still physically present — carry elevated depression and suicidal ideation risk. Assessment must include the caregiver explicitly.[55]

Distinguish carefully: passive wish for death ("I'm ready for this to be over" — common and often contextually appropriate in both patients and caregivers), active suicidal ideation with plan (requires immediate psychiatric engagement — for caregivers, requires safety assessment including access to the patient's medications and the caregiver's own firearms), and impulsive self-harm risk (the bvFTD patient's disinhibition may lead to dangerous behavior that is not intentionally suicidal but carries lethal risk — this is a safety management issue, not a psychiatric emergency). Do not avoid these questions. Ask the caregiver directly: "Have things ever gotten so hard that you've thought about hurting yourself?"

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"The FTD family is the one I worry about most after the patient dies. The Alzheimer's caregiver has usually had a slow goodbye and a community around them. The bvFTD caregiver has been grieving alone for years, has been socially isolated by the disease, and when the patient finally dies, there is no one at the memorial who really understands what they survived. Bereavement follow-up in FTD is not a courtesy call — it is a clinical safety check."
— Waldo, NP · Terminal2
S13FamilyEveryone

Family Guide

Plain language for families living with frontotemporal dementia. Share, print, or read aloud. You are not alone.

If you are reading this, someone you love has frontotemporal dementia — and you have probably already been through more than most families face in a lifetime. The years of unexplained behavior changes, the misdiagnoses, the financial and legal damage, the isolation, the grief of watching your person become someone you do not recognize — we know. Your hospice team knows. And we are here not just for the person in the bed but for you, because you have been carrying this alone for far too long. What you are seeing is a disease — not a choice your person made. The brain damage from FTD affects judgment, empathy, impulse control, and language. Everything that follows is a guide to help you understand what is happening and what you can do.[54]

Si está leyendo esto, alguien a quien ama tiene demencia frontotemporal. Su equipo de hospicio está aquí para usted y para su ser querido. Lo que está viendo es una enfermedad, no una elección. Próximamente más información en español.

What You May See
  • Personality and behavior that is unrecognizable: The disease has damaged the parts of the brain that control judgment, empathy, impulse, and social behavior. What you are seeing is not a character change — it is neurological damage. The things your person says or does that are embarrassing, hurtful, or frightening are caused by the disease, not by a choice. This does not make them easier to witness, but it means you do not need to feel ashamed of your person.
  • Difficulty speaking or finding words: In language variant FTD, your person may understand far more than they can express. Speak to them normally and clearly. Use the communication device or method your hospice team set up. Give them time to respond. Assume understanding even when there is no verbal response — they may still know exactly what you are saying.
  • Eating much more than usual or putting non-food items in the mouth: This is called hyperorality — a neurological symptom from frontal lobe damage. The eating urge is not controllable by willpower. You cannot talk them out of it. Manage the environment: keep unsafe items out of reach, lock cabinets with cleaning products or medications, and keep preferred safe foods accessible. Sweet cravings are extremely common.
  • Repetitive behaviors or routines: Your person may repeat the same action, phrase, or behavior many times — walking the same route, asking the same question, performing the same ritual. This is neurological, not deliberate. Redirection works better than confrontation. Match the routine rather than interrupt it when it is safe. Interrupting may cause agitation; allowing it costs nothing.
  • In FTD-ALS — progressive difficulty breathing, speaking, or swallowing: Your person may have a breathing machine (NIV/BiPAP) that helps them breathe more comfortably. There is a specific plan for when breathing gets harder. Call the hospice nurse at the first sign of breathing difficulty. Do not call 911 first. Your comfort medication kit is at the bedside and ready to help.
How You Can Help
  • Do not argue, confront, or try to reason: The parts of the brain that process logic, consequences, and social rules are the parts the disease damages. Arguments will not change behavior — they will escalate it. Instead: redirect, distract, and remove the trigger. If your person is fixated on going somewhere, redirect to a different activity rather than explaining why they cannot go.
  • Keep the daily routine consistent: Same wake time, same meal times, same activity sequence. Structure is the most powerful behavioral intervention you have. Post the routine where everyone can see it. Tell every aide and visitor to follow it. Changes to routine can trigger agitation.
  • Use the communication system: If your hospice team set up a communication board, picture book, or tablet app, use it consistently. Point to pictures. Use short sentences. Give your person time to respond. Their understanding is almost certainly better than their ability to speak.
  • Lock up everything dangerous: Medications, car keys, financial documents, credit cards, cleaning products, sharp objects. The impulsivity from FTD means your person may grab and use anything within reach. This is not about trust — it is about brain damage and safety.
  • Take care of yourself — this is not optional: You have been carrying this longer than most people can imagine. Your exhaustion is real. Your grief is real. Your anger is real and it is allowed. Call your hospice team when you need support — not just when the patient does. Ask about AFTD caregiver support groups. Accept respite when it is offered. You cannot sustain this alone, and asking for help is not weakness — it is survival.[54]
📞 Call the hospice nurse immediately if you see:

New or worsening breathing difficulty (gasping, using neck muscles to breathe, blue lips or fingertips, unable to speak in full sentences) — especially in FTD-ALS; seizure activity (rhythmic jerking, loss of consciousness, unresponsiveness that is different from normal sleep — turn on side, protect head, do not put anything in the mouth, time the seizure, give emergency medication if instructed); sudden inability to swallow (choking, drooling, food or liquid coming from the nose — stop all oral intake immediately); falls with head injury or inability to get up; aggressive behavior that you cannot safely manage (if you are in immediate danger, call 911 first, then call hospice); any sudden change in responsiveness or behavior that is different from the usual pattern. Your hospice number is available 24 hours — call any time, day or night. That is what it is there for.

🧬 A Conversation for Adult Children: Genetics

If your family member's FTD is caused by a known genetic mutation (C9orf72, GRN, or MAPT — your neurologist or hospice team can tell you), then each biological child of the patient has a 50% chance of carrying the same mutation. This does not mean they will definitely get the disease, but it means genetic counseling is strongly recommended. Genetic counseling provides information, testing options, access to research trials for people who carry mutations but don't have symptoms yet, and guidance for family planning decisions. Ask your hospice team for a genetic counseling referral. This is one of the most important things you can do for your family's future. You do not have to face this alone, and you do not have to make decisions without information.[51]

🙏 You are not just watching. You are present — and that presence matters more than you know. Research consistently shows that patients with engaged, supported family caregivers have better comfort outcomes, less agitation, and greater peace in their final time. Your being here, even when it is hard, even when the person you knew seems unreachable, is one of the most important things happening in this home. You are the treatment team. Let us help you stay strong enough to be here.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. FTD-specific, field-tested, grounded in the reality of these families. Not guidelines — real.

  1. 01
    The first question you ask at a bvFTD enrollment visit is not about symptoms. It is about the years before the diagnosis. "Tell me what the last few years were like before you got this diagnosis." Then stop talking. The answer will tell you everything — the financial devastation, the legal problems, the relational rupture, the diagnostic odyssey, the emotional exhaustion. The family who has never had anyone ask this question and sit with the answer will tell you things in the first ten minutes that reshape the entire care plan. They've been carrying these years alone because no one in the medical system has ever asked what it was like to live through the pre-diagnosis period. You are not doing history-taking. You are witnessing. And it is one of the most clinically powerful things you will ever do in hospice.
  2. 02
    The behavioral symptom regimen in bvFTD starts with trazodone and sertraline. Not antipsychotics. If the patient arrives with a behavioral symptom regimen that does not include trazodone, the pharmacological approach has missed the single most effective and best-evidenced tool for FTD specifically. I start trazodone 50 mg at bedtime at enrollment — every bvFTD enrollment, no exceptions. I titrate to behavioral effect over the following weeks. I add sertraline 50 mg in the morning if we need more. This combination addresses the serotonergic deficit that drives the disinhibition and compulsive behaviors of bvFTD more effectively than any antipsychotic. The number of bvFTD patients I have inherited on haloperidol and olanzapine who had never been tried on trazodone is a failure of the system. Be the clinician who fixes the regimen.[27]
  3. 03
    The genetic counseling referral for adult children of familial FTD is a clinical obligation you cannot delay. Make the call before you leave the first visit or write the referral order while you are still in the patient's home. The C9orf72, GRN, or MAPT mutation carrier who does not know they carry it cannot make informed decisions about clinical trials, reproductive planning, or neurological surveillance. The ALLFTD consortium has active studies for presymptomatic carriers. The adult child who gets the referral today may be able to enroll in a prevention trial that did not exist five years ago. I have seen this referral change the trajectory of an entire family — not the patient's trajectory, but the next generation's. Five minutes of your time. A phone call. It is the highest-impact referral you will make in FTD care.[51]
  4. 04
    The family is grieving a stranger. This is the sentence you need to carry into every bvFTD home. The Alzheimer's caregiver watches their person gradually fade — sad, slow, recognizable. The bvFTD caregiver watches their person become someone they do not know. Someone cruel. Someone with no empathy. Someone who says things the person they married would never have said. The body is the same. The person is gone. And the grief has no cultural script — there is no card for "I'm sorry the disease turned your husband into someone who frightens you." When the caregiver breaks down and says "I don't even know who this is anymore," your job is not to explain the neuroscience. Your job is to say: "You're right. This is not who they were. And what you're feeling right now is one of the hardest griefs there is. Let us help you carry it."[55]
  5. 05
    The AAC device must work for everyone in the house — not just the speech therapist who set it up. I have walked into PPA homes where the patient has a beautiful, expensive communication tablet that no one in the family knows how to operate. The aide doesn't know. The nighttime caregiver doesn't know. The patient stares at it and the people around them stare at it and no one communicates. Put the instructions on the refrigerator. Do a five-minute training with every person who enters that home. Include the communication method in the care plan in language a high school student could follow. The PPA patient who has residual cognition but no voice and no working communication system is living in a prison. You have the key. Use it.[29]
  6. 06
    In FTD-ALS, the NIV withdrawal conversation happens at enrollment — in daylight, in calm, with the family sitting down. I tell them exactly what will happen: "There will come a point when the mask is no longer helping — when the disease has progressed past what the ventilator can support. When that point comes, we will remove the mask, we will give medication to ensure your person does not suffer, and they will die peacefully. We will be here." Then I prepare: morphine drawn, midazolam drawn, syringes labeled, dosing written on the refrigerator. The family who has heard this in advance, who has had time to sit with it, who has seen the medications ready — that family can consent calmly when the moment comes. The family hearing it for the first time at 2 AM during an acute respiratory crisis cannot. This is the most important conversation in FTD-ALS care. Have it first.[49]
  7. 07
    The legal and financial crisis at enrollment is not a social work nice-to-have — it is a clinical emergency. FTD strikes in the working years. By the time I arrive, the family has usually lost the patient's income, may have lost savings to disinhibited spending or bad financial decisions made during the pre-diagnosis period, and may be facing guardianship proceedings because no power of attorney was executed while the patient still had capacity. If there is any residual decision-making capacity — any at all — the advance directive and power of attorney must be completed at the first visit. Not the second visit. The first. I have seen families lose the window between my first and second visit because FTD cognitive decline is unpredictable. Social work engagement on day one. Financial resource referral on day one. Legal assessment on day one. This is not paperwork. This is survival.[53]
  8. 08
    Younger caregivers need different support. The FTD caregiver is often 50–55 years old, still working, still raising kids, still paying a mortgage. They are not the 82-year-old Alzheimer's caregiver the hospice system was designed for. They need evening availability because they work during the day. They need respite aides who can manage bvFTD behavioral symptoms — not every aide is prepared for a patient who may be aggressive, sexually inappropriate, or determined to leave the house. They need financial counseling because they are facing 20–30 years of life after their spouse dies, with depleted savings and interrupted careers. They need someone to ask about their children — the teenager watching their parent become a stranger carries a grief that no one at school understands. Tailor the support plan. Ask what they actually need. It will not be what the standard hospice support package offers.[54]
  9. 09
    Every bvFTD enrollment needs a disinhibition safety plan. I assess it at the first visit: Does the patient attempt to leave the home? Are they physically aggressive? Are there sexually inappropriate behaviors? Do they attempt to drive? Can they access the stove, medications, car keys, or firearms? Then I build the plan: locked exits with fire-safe egress, secured kitchen, car disabled or keys removed, all firearms out of the house (this is non-negotiable — a disinhibited person with access to a firearm is a life-threatening safety hazard), medications locked, financial access removed. I teach the caregiver: do not confront, do not argue, redirect and distract. I write the plan in the chart and I review it with every team member who enters that home. The safety plan is not paperwork. It is the thing that prevents the call that no one can undo.[30]
  10. 10
    Here is what I have learned about being present in an FTD home. The person in the bed may not know you. They may say something cruel. They may not react to your presence at all. The family sitting at the kitchen table is exhausted, isolated, financially devastated, and grieving someone who is still breathing. The disease has taken everything familiar and left something unrecognizable. And you walk in. You do not fix any of it. You cannot reverse the frontal lobe damage. You cannot give the family back the person they knew. You cannot undo the years of misdiagnosis and suffering that preceded your arrival. What you can do is be steady. Be present. Be the person who shows up, who asks the hard questions, who manages the symptoms, who calls the genetic counselor, who starts the trazodone, who teaches the aide how to use the communication board, who asks the caregiver when the last time they slept was. You are the person who walks into the wreckage and says: I see this. I understand what happened here. And I will be here until the end. That is enough. That is everything.
— Waldo, NP
REFClinician

References

Peer-reviewed citations supporting all 14 sections. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

1
Knopman DS, Roberts RO. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci. 2011;45(3):330-335.
PMID 21584654 Observational
2
Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25(2):130-137.
PMID 23611343 Review
3
Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736-1743.
PMID 27037234 Observational
4
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477.
PMID 21810890 DOI Diagnostic Criteria
5
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.
PMID 21325651 DOI Diagnostic Criteria
6
Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59(7):1077-1079.
PMID 12370467 Observational
7
Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134(Pt 9):2582-2594.
PMID 21840887 Review
8
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
PMID 21944778 DOI Discovery
9
Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
PMID 21944779 DOI Discovery
10
Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916-919.
PMID 16862116 Discovery
11
Ghetti B, Oblak AL, Boeve BF, et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations. Neuropathol Appl Neurobiol. 2015;41(1):24-46.
PMID 25556536 Review
12
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133.
PMID 17023659 DOI Discovery
13
Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
PMID 11520930 Review
14
Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(2):126-133.
PMID 21382304 Observational
15
Rosness TA, Engedal K, Chemali Z. Frontotemporal dementia: an updated clinician's guide. J Geriatr Psychiatry Neurol. 2016;29(5):271-280.
PMID 27502299 Review
16
Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149-156.
PMID 23290598 DOI RCT
17
Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84-87.
PMID 17194818 Observational
18
Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003;18(1):67-72.
PMID 12497557 Observational
19
Benussi A, Padovani A, Borroni B. Phenotypic heterogeneity of monogenic frontotemporal dementia. Front Bioeng Biotechnol. 2015;3:171.
PMID 26579519 Review
20
Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study. Lancet Neurol. 2015;14(3):253-262.
PMID 25662776 Observational
21
Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476-486.
PMID 20971753 Review
22
Finger EC. Frontotemporal dementias. Continuum (Minneap Minn). 2016;22(2 Dementia):464-489.
PMID 27042904 Review
23
Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016;138 Suppl 1:211-221.
PMID 27502123 Review
24
Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 2007;6(11):1004-1014.
PMID 17945154 Review
25
Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24(6):542-549.
PMID 21986680 Review
26
Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35(2):339-374.
PMID 28410663 Review
27
Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355-359.
PMID 15178953 DOI RCT
28
Herrmann N, Black SE, Bhatt S, et al. A randomized, double-blind, placebo-controlled trial of citalopram for agitation in frontotemporal lobar degeneration (CAFT trial). Lancet Psychiatry. 2022;9(2):107-117.
PMID 35026146 RCT
29
Jokel R, Meltzer J. AAC intervention in primary progressive aphasia: taking advantage of preserved language modalities. Aphasiology. 2017;31(6):673-690.
Observational
30
O'Connor CM, Clemson L, Brodaty H, et al. The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study. Disabil Rehabil. 2019;41(3):299-310.
PMID 29048235 Observational
31
Särkämö T, Tervaniemi M, Laitinen S, et al. Music listening enhances cognitive recovery and mood after middle cerebral artery stroke. Brain. 2008;131(Pt 3):866-876.
PMID 18287122 RCT
32
Mullen B, Champagne T, Krishnamurthy S, Dickson D, Gao RX. Exploring the safety and therapeutic effects of deep pressure stimulation using a weighted blanket. Occup Ther Ment Health. 2008;24(1):65-89.
Observational
33
Mitchell G, McCormack B, McCance T. Therapeutic use of dolls for people living with dementia: a critical review of the literature. Dementia (London). 2016;15(5):976-1001.
PMID 25070966 Systematic Review
34
Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44-50.
PMID 29398248 Observational
35
Beagle AJ, Darber W, Engelen JJ, et al. Seizure frequency in C9orf72 frontotemporal dementia. Neurology. 2020;95(18):e2476-e2484.
PMID 32817176 Observational
36
McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020;11(11):CD009178.
PMID 33189083 Meta-Analysis
37
Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids' supplementation in Alzheimer's disease: a systematic review. Nutr Neurosci. 2018;21(8):529-538.
PMID 28466678 Systematic Review
38
Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33-44.
PMID 24381967 DOI RCT
39
Annweiler C, Montero-Odasso M, Llewellyn DJ, et al. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis. 2013;37(1):147-171.
PMID 23948884 Meta-Analysis
40
Cunnane SC, Courchesne-Loyer A, Vandenberghe C, et al. Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer's disease. Front Mol Neurosci. 2016;9:53.
PMID 27458340 Review
41
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial (GEM study). JAMA. 2008;300(19):2253-2262.
PMID 19017911 DOI RCT
42
Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M. Clinical risks of St John's Wort (Hypericum perforatum) co-administration. Expert Opin Drug Metab Toxicol. 2017;13(10):1047-1062.
PMID 28882074 Review
43
Liscic RM, Storandt M, Cairns NJ, Morris JC. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol. 2007;64(4):535-540.
PMID 17420315 Observational
44
Loi SM, Mazzone A, Zatt S, et al. Frontotemporal dementia: diagnostic delay and the role of clinical, cognitive, and neuroimaging features. Alzheimers Dement (Amst). 2022;14(1):e12357.
PMID 36091498 Observational
45
Riedl L, Mackenzie IR, Förstl H, et al. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat. 2014;10:297-310.
PMID 24600222 Review
46
National Hospice and Palliative Care Organization (NHPCO). Hospice eligibility criteria for dementia. NHPCO Clinical Practice Guidelines. Updated 2023.
Guideline
47
Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17-22.
PMID 16401839 Systematic Review
48
Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
PMID 28980624 Review
49
Heritier Barras AC, Adler D, Iancu Ferfoglia R, et al. Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group. Swiss Med Wkly. 2013;143:w13830.
PMID 23888405 Expert Opinion
50
Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.
PMID 18254072 Meta-Analysis
51
Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65(11):1817-1819.
PMID 16344531 Observational
52
Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9-15.
PMID 12807591 DOI Validation
53
Diehl-Schmid J, Schmidt EM, Nunnemann S, et al. Caregiver burden and needs in frontotemporal dementia. J Geriatr Psychiatry Neurol. 2013;26(4):221-229.
PMID 24212240 Observational
54
Caceres BA, Frank MO, Jun J, Martelly MT, Sadarangani T, de Sales PC. Family caregivers of patients with frontotemporal dementia: an integrative review. Int J Nurs Stud. 2016;55:71-84.
PMID 26612696 Systematic Review
55
Oyebode JR, Bradley P, Allen JL. Relatives' experiences of frontal-variant frontotemporal dementia. Qual Health Res. 2013;23(2):156-166.
PMID 23132766 Qualitative
56
Association for Frontotemporal Degeneration (AFTD). FTD caregiver support and resources. AFTD. Available at: theaftd.org. Accessed 2025.
Resource
57
ALLFTD (Advancing Research and Treatment for Frontotemporal Lobar Degeneration) Consortium. Clinical trials and presymptomatic carrier surveillance. ALLFTD. Available at: allftd.org. Accessed 2025.
Resource
58
Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375-398.
PMID 20369906 Review
59
Hodges JR, Piguet O. Progress and challenges in frontotemporal dementia research: a 20-year review. J Alzheimers Dis. 2018;62(3):1467-1480.
PMID 29562545 Review
60
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis — drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73(15):1218-1226.
PMID 19822872 Practice Parameter
61
Riluzole (Rilutek) prescribing information. Sanofi-Aventis. FDA-approved label. Updated 2023.
Guideline
62
Arevalo-Rodriguez I, Smailagic N, Roqué-Figuls M, et al. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2021;7(7):CD010783.
PMID 34313334 Meta-Analysis
63
Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(Pt 3):847-852.
PMID 22271664 Observational

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. FTD-specific considerations: document the specific FTD variant, genetic status, ALS overlap status, behavioral safety plan details, NIV status, communication method, caregiver burnout assessment, genetic counseling referral status, and advance directive completion status. This text is stored only in your browser session.